Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value
[December 28, 2020] Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value MIAMI, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the âCompanyâ), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions, announced today the Company's Board of directors has elected to sell 100% of its Mycotopia Therapies subsidiary to 20/20 Global Inc. (OTC Pink: TWGL) for $350,000 while simultaneously acquiring approximately 75.77% of 20/20 Globalâs outstanding...
Source: tmcnet.com